Table 1 Clinical characteristics of patients receiving Convalescent Plasma Therapy
No. | Patient | Sex | Age (years) | Stage of disease | Days from symptom onset to admission | Days from symptom onset to CPT | Site of infection | Main symptoms | Comorbidities |
|---|---|---|---|---|---|---|---|---|---|
1 | SUN | M | 50 | Severe COVID-19 | 5 | 9 | Lung | Fever, cough, dyspnea | Hypertension, diabetes mellitus type 2, anxiety disorder |
2 | HSD | M | 67 | Severe COVID-19 | 7 | 16 | Lung | Fever, cough, nausea, dyspnea | CAD post PCI, diabetes mellitus type 2, hypertension |
3 | YHA | F | 50 | Severe COVID-19 | 7 | 13 | Lung | Dyspnea, fever, cough, diarrhea | None |
4 | AMH | F | 45 | Severe COVID-19 | 4 | 10 | Lung | Dyspnea, fever, cough, myalgia | Diabetes mellitus type 2 |
5 | ERN | M | 55 | Severe COVID-19 | 7 | 15 | Lung | Dyspnea, cough, fever | Diabetes mellitus type 2 |
6 | DSO | M | 40 | Severe COVID-19 | 3 | 11 | Lung | Dyspnea, fever, fatigue, nausea | None |
7 | RMD | M | 51 | Severe COVID-19 | 5 | 11 | Lung | Fever, diarrhea | Polycythemia vera |
8 | HUM | F | 74 | Severe COVID-19 | 14 | 19 | Lung | Nausea, general weakness, dyspnea | Diabetes mellitus type 2, arrhythmia (frequent VES) |